Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL026 (DMT) with or without SSRIs in MDD
NCT05553691Phase 1Completed
- Sponsor
- Small Pharma
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPL026 in major depressive disorder (MDD) (2 cohorts), sponsored by Small Pharma. Primary endpoints: Adverse Events at Day 29, Laboratory biochemistry parameters at Day 1 and 3 more. Started Dec 2022; status: completed.
02
Drugs
SPL026
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05553691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553691.